VELOXIS PHARMACEUTICALS A/S: Financial statements 2025
CVR: 26527767
Source: annual report 2025, Danish Business Authority
01/04/2024 – 31/03/2025
VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2025. Equity in the 2025 report amounted to USD 88,648,000. The solvency ratio was 98.6%. The company had 1 employee in the financial year.
- Equity
- USD 88,648,000
- Total Assets
- USD 89,916,000
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | - | - | 88.6M USD | 1 |
| 2024 | - | - | - | -10.5M USD | 1 |
| 2023 | - | - | - | 2.8M USD | 1 |
| 2022 | 0 USD | 0 USD | 2.1M USD | 2.9M USD | - |
| 2021 | 45.3M USD | 45.3M USD | 1.1B USD | 1.3B USD | - |
Official annual report
How creditworthy is VELOXIS PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of September 4, 2025, Kenro Yuzaki has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of September 4, 2025, Yusuke Hiramatsu has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
About VELOXIS PHARMACEUTICALS A/S
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.
